GoodRx (NASDAQ:GDRX) Given New $7.00 Price Target at Citigroup

GoodRx (NASDAQ:GDRX) had its price objective cut by Citigroup from $10.00 to $7.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

GDRX has been the topic of a number of other research reports. Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research note on Friday, August 9th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. Finally, UBS Group reduced their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.86.

GoodRx Price Performance

GDRX stock opened at $4.15 on Wednesday. The stock has a market cap of $1.57 billion, a PE ratio of -138.33, a P/E/G ratio of 3.22 and a beta of 1.39. GoodRx has a 12 month low of $4.09 and a 12 month high of $9.26. The company has a 50-day moving average price of $6.55 and a 200 day moving average price of $7.42. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.17% of the company’s stock.

Institutional Investors Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. American Century Companies Inc. acquired a new position in shares of GoodRx during the second quarter worth $18,183,000. Point72 Asset Management L.P. acquired a new position in GoodRx during the 3rd quarter valued at about $11,295,000. Rubric Capital Management LP increased its position in GoodRx by 76.5% during the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock valued at $29,147,000 after buying an additional 1,619,748 shares in the last quarter. Millennium Management LLC raised its stake in GoodRx by 36.5% in the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after buying an additional 1,102,758 shares during the last quarter. Finally, Picton Mahoney Asset Management acquired a new stake in GoodRx in the first quarter worth about $3,467,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.